Skip to main content
Top
Published in: BMC Urology 1/2005

Open Access 01-12-2005 | Research article

Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder

Authors: Kimberly D Kyker, Jean Coffman, Robert E Hurst

Published in: BMC Urology | Issue 1/2005

Login to get access

Abstract

Background

Interstital cystitis is often treated with exogenous glycosaminoglycans such as heparin, chondroitin sulphate (Uracyst), hyaluronate (Cystistat) or the semi-synthetic pentosan polysulphate (Elmiron). The mechanism of action is presumed to be due to a coating of the bladder surface to replace the normally present chondroitin sulphate and heparan sulphate lost as a result of the disease. This study used fluorescent labelled chondroitin sulphate to track the distribution of glycosaminoglycans administered intravesically to mouse bladder that had been damaged on the surface.

Methods

The surfaces of mouse bladders were damaged by 3 mechanisms – trypsin, 10 mM HCl, and protamine sulphate. Texas Red-labeled chondroitin sulphate was instilled into the bladders of animals with damaged bladders and controls instilled only with saline. Bladders were harvested, frozen, and sectioned for examination by fluorescence.

Results

The normal mouse bladder bound a very thin layer of the labelled chondroitin sulphate on the luminal surface. Trypsin- and HCl-damaged bladders bound the labelled chondroitin sulphate extensively on the surface with little penetration into the bladder muscle. Protamine produced less overt damage, and much less labelling was seen, presumably due to loss of the label as it complexed with the protamine intercalated into the bladder surface.

Conclusion

Glycosaminoglycan administered intravesically does bind to damaged bladder. Given that the changes seen following bladder damage resemble those seen naturally in interstitial cystitis, the mechanisms proposed for the action of these agents is consistent with a coating of damaged bladder.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lukban JC, Parkin JV, Holzberg AS, Caraballo R, Kellogg-Spadt S, Whitmore KE: Interstitial cystitis and pelvic floor dysfunction: a comprehensive review. Pain Med. 2001, 2: 60-71. 10.1046/j.1526-4637.2001.002001060.x.CrossRefPubMed Lukban JC, Parkin JV, Holzberg AS, Caraballo R, Kellogg-Spadt S, Whitmore KE: Interstitial cystitis and pelvic floor dysfunction: a comprehensive review. Pain Med. 2001, 2: 60-71. 10.1046/j.1526-4637.2001.002001060.x.CrossRefPubMed
2.
go back to reference Sand PK: Chronic pain syndromes of gynecologic origin. J Reprod Med. 2004, 49: 230-234.PubMed Sand PK: Chronic pain syndromes of gynecologic origin. J Reprod Med. 2004, 49: 230-234.PubMed
3.
go back to reference Messing EM, Stamey TA: Interstitial cystitis: early diagnosis, pathology, and treatment. Urology. 1978, 12: 381-392. 10.1016/0090-4295(78)90286-8.CrossRefPubMed Messing EM, Stamey TA: Interstitial cystitis: early diagnosis, pathology, and treatment. Urology. 1978, 12: 381-392. 10.1016/0090-4295(78)90286-8.CrossRefPubMed
4.
go back to reference Elbadawi AE, Light JK: Distinctive ultrastructural pathology of nonulcerative interstitial cystitis: new observations and their potential significance in pathogenesis. Urol Int. 1996, 56: 137-162.CrossRefPubMed Elbadawi AE, Light JK: Distinctive ultrastructural pathology of nonulcerative interstitial cystitis: new observations and their potential significance in pathogenesis. Urol Int. 1996, 56: 137-162.CrossRefPubMed
5.
go back to reference Keay SK, Szekely Z, Conrads TP, Veenstra TD, Barchi JJJ, Zhang CO, Koch KR, Michejda CJ: An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proc Natl Acad Sci U S A. 2004, 101: 11803-11808. 10.1073/pnas.0404509101.CrossRefPubMedPubMedCentral Keay SK, Szekely Z, Conrads TP, Veenstra TD, Barchi JJJ, Zhang CO, Koch KR, Michejda CJ: An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proc Natl Acad Sci U S A. 2004, 101: 11803-11808. 10.1073/pnas.0404509101.CrossRefPubMedPubMedCentral
6.
go back to reference Slobodov G, Feloney M, Gran C, Kyker KD, Hurst RE, Culkin DJ: Abnormal Expression of Molecular Markers for Bladder Impermeability and Differentiation in Urothelium of Interstitial Cystitis Patients. J Urol. 2004, 171: 1554-1558. 10.1097/01.ju.0000118938.09119.a5.CrossRefPubMed Slobodov G, Feloney M, Gran C, Kyker KD, Hurst RE, Culkin DJ: Abnormal Expression of Molecular Markers for Bladder Impermeability and Differentiation in Urothelium of Interstitial Cystitis Patients. J Urol. 2004, 171: 1554-1558. 10.1097/01.ju.0000118938.09119.a5.CrossRefPubMed
7.
go back to reference Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, Patton K, Shackelford, DL, Stein P, Parsons CL: A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology. 1996, 48: 817-821. 10.1016/S0090-4295(96)00322-6.CrossRefPubMed Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, Patton K, Shackelford, DL, Stein P, Parsons CL: A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology. 1996, 48: 817-821. 10.1016/S0090-4295(96)00322-6.CrossRefPubMed
8.
go back to reference Grist M, Chakraborty J: Identification of a mucin layer in the urinary bladder. Urology. 1994, 44: 26-33. 10.1016/S0090-4295(94)80005-7.CrossRefPubMed Grist M, Chakraborty J: Identification of a mucin layer in the urinary bladder. Urology. 1994, 44: 26-33. 10.1016/S0090-4295(94)80005-7.CrossRefPubMed
9.
go back to reference Hurst RE, Zebrowski R: Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J Urol. 1994, 152: 1641-1645.PubMed Hurst RE, Zebrowski R: Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J Urol. 1994, 152: 1641-1645.PubMed
10.
go back to reference Nickel JC, Cornish J: Ultrastructural study of an antibody-stabilized bladder surface: a new perspective on the elusive glycosaminoglycan layer. World J Urol. 1994, 12: 11-14. 10.1007/BF00182045.CrossRefPubMed Nickel JC, Cornish J: Ultrastructural study of an antibody-stabilized bladder surface: a new perspective on the elusive glycosaminoglycan layer. World J Urol. 1994, 12: 11-14. 10.1007/BF00182045.CrossRefPubMed
11.
go back to reference Hurst RE, Rhodes SW, Adamson PB, Parsons CL, Roy JB: Functional and structural characteristics of the glycosaminoglycans of the bladder luminal surface. J Urol. 1987, 138: 433-437.PubMed Hurst RE, Rhodes SW, Adamson PB, Parsons CL, Roy JB: Functional and structural characteristics of the glycosaminoglycans of the bladder luminal surface. J Urol. 1987, 138: 433-437.PubMed
12.
go back to reference Parsons CL, Forrest J, Nickel JC, Evans R, Lloyd LK, Barkin J, Mosbaugh PG, Kaufman DM, Hernandez-Graulau JM, Atkinson L, Albrecht D: Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology. 2002, 59: 329-333. 10.1016/S0090-4295(01)01586-2.CrossRefPubMed Parsons CL, Forrest J, Nickel JC, Evans R, Lloyd LK, Barkin J, Mosbaugh PG, Kaufman DM, Hernandez-Graulau JM, Atkinson L, Albrecht D: Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology. 2002, 59: 329-333. 10.1016/S0090-4295(01)01586-2.CrossRefPubMed
13.
go back to reference Parsons CL, Greenspan C, Moore SW, Mulholland SG: Role of surface mucin in primary antibacterial defense of bladder. Urology. 1977, 9: 48-52. 10.1016/0090-4295(77)90284-9.CrossRefPubMed Parsons CL, Greenspan C, Moore SW, Mulholland SG: Role of surface mucin in primary antibacterial defense of bladder. Urology. 1977, 9: 48-52. 10.1016/0090-4295(77)90284-9.CrossRefPubMed
14.
go back to reference Lewis SA, Berg JR, Kleine TJ: Modulation of epithelial permeability by extracellular macromolecules. Physiol Rev. 1995, 75: 561-589.PubMed Lewis SA, Berg JR, Kleine TJ: Modulation of epithelial permeability by extracellular macromolecules. Physiol Rev. 1995, 75: 561-589.PubMed
15.
go back to reference Negrete HO, Lavelle JP, Berg J, Lewis SA, Zeidel ML: Permeability properties of the intact mammalian bladder epithelium. Am J Physiol. 1996, 271: F886-F894.PubMed Negrete HO, Lavelle JP, Berg J, Lewis SA, Zeidel ML: Permeability properties of the intact mammalian bladder epithelium. Am J Physiol. 1996, 271: F886-F894.PubMed
16.
go back to reference Bade JJ, Laseur M, Nieuwenburg A, Van der Weele LT, Mensink HJA: A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis. Br J Urol. 1997, 79: 168-171.CrossRefPubMed Bade JJ, Laseur M, Nieuwenburg A, Van der Weele LT, Mensink HJA: A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis. Br J Urol. 1997, 79: 168-171.CrossRefPubMed
17.
go back to reference Nordling J, Jorgensen S, Kallestrup E: Cystistat for the treatment of interstitial cystitis: a 3-year follow-up study. Urology. 2001, 57: 123-10.1016/S0090-4295(01)01079-2.CrossRefPubMed Nordling J, Jorgensen S, Kallestrup E: Cystistat for the treatment of interstitial cystitis: a 3-year follow-up study. Urology. 2001, 57: 123-10.1016/S0090-4295(01)01079-2.CrossRefPubMed
18.
go back to reference Steinhoff G, Ittah B, Rowan S: The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol. 2002, 9: 1454-1458.PubMed Steinhoff G, Ittah B, Rowan S: The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol. 2002, 9: 1454-1458.PubMed
19.
go back to reference Parsons CL, Housley T, Schmidt JD, Lebow D: Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994, 73: 504-507.CrossRefPubMed Parsons CL, Housley T, Schmidt JD, Lebow D: Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994, 73: 504-507.CrossRefPubMed
20.
go back to reference Hurst RE, Roy JB, Parsons CL: The role of glycosaminoglycans in normal bladder physiology and the pathophysiology of interstitial cystitis. Interstitial Cystitis. Edited by: Sant GR. 1997, Philadelphia, Lippincott-Raven, 93-100. Hurst RE, Roy JB, Parsons CL: The role of glycosaminoglycans in normal bladder physiology and the pathophysiology of interstitial cystitis. Interstitial Cystitis. Edited by: Sant GR. 1997, Philadelphia, Lippincott-Raven, 93-100.
21.
go back to reference Tzan CJ, Berg J, Lewis SA: Effect of protamine sulfate on the permeability properties of the mammalian urinary bladder. J Membr Biol. 1993, 133: 227-242.CrossRefPubMed Tzan CJ, Berg J, Lewis SA: Effect of protamine sulfate on the permeability properties of the mammalian urinary bladder. J Membr Biol. 1993, 133: 227-242.CrossRefPubMed
22.
go back to reference Giedrojc J, Klimiuk M, Radziwon P, Kloczko J, Bielawiec M, Breddin HK: Comparative study on the in vitro and in vivo activities of heparinoids derivative investigated on the animal model. J Cardiovasc Pharmacol. 1999, 34: 340-345. 10.1097/00005344-199909000-00004.CrossRefPubMed Giedrojc J, Klimiuk M, Radziwon P, Kloczko J, Bielawiec M, Breddin HK: Comparative study on the in vitro and in vivo activities of heparinoids derivative investigated on the animal model. J Cardiovasc Pharmacol. 1999, 34: 340-345. 10.1097/00005344-199909000-00004.CrossRefPubMed
23.
go back to reference Brecher AS, Adamu MT: Coagulation protein function: enhancement of the anticoagulant effect of acetaldehyde by sulfated glycosaminoglycans. Dig Dis Sci. 2001, 46: 2033-2042. 10.1023/A:1010668005729.CrossRefPubMed Brecher AS, Adamu MT: Coagulation protein function: enhancement of the anticoagulant effect of acetaldehyde by sulfated glycosaminoglycans. Dig Dis Sci. 2001, 46: 2033-2042. 10.1023/A:1010668005729.CrossRefPubMed
24.
go back to reference Boucher WS, Letourneau R, Huang M, Kempuraj D, Green M, Sant GR, Theoharides TC: Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress. J Urol. 2002, 167: 380-384. 10.1097/00005392-200201000-00105.CrossRefPubMed Boucher WS, Letourneau R, Huang M, Kempuraj D, Green M, Sant GR, Theoharides TC: Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress. J Urol. 2002, 167: 380-384. 10.1097/00005392-200201000-00105.CrossRefPubMed
25.
go back to reference Chiang G, Patra P, Letourneau R, Jeudy S, Boucher W, Green M, Sant GR, Theoharides TC: Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis. J Urol. 2000, 164: 2119-2125. 10.1097/00005392-200012000-00075.CrossRefPubMed Chiang G, Patra P, Letourneau R, Jeudy S, Boucher W, Green M, Sant GR, Theoharides TC: Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis. J Urol. 2000, 164: 2119-2125. 10.1097/00005392-200012000-00075.CrossRefPubMed
26.
go back to reference Theoharides TC, Patra P, Boucher W, Letourneau R, Kempuraj D, Chiang G, Jeudy S, Hesse L, Athanasiou A: Chondroitin sulphate inhibits connective tissue mast cells. Br J Pharmacol. 2000, 131: 1039-1049. 10.1038/sj.bjp.0703672.CrossRefPubMedPubMedCentral Theoharides TC, Patra P, Boucher W, Letourneau R, Kempuraj D, Chiang G, Jeudy S, Hesse L, Athanasiou A: Chondroitin sulphate inhibits connective tissue mast cells. Br J Pharmacol. 2000, 131: 1039-1049. 10.1038/sj.bjp.0703672.CrossRefPubMedPubMedCentral
27.
go back to reference Lewis SA, Clausen C: Urinary proteases degrade epithelial sodium channels. J Membr Biol. 1991, 122: 77-88.CrossRefPubMed Lewis SA, Clausen C: Urinary proteases degrade epithelial sodium channels. J Membr Biol. 1991, 122: 77-88.CrossRefPubMed
Metadata
Title
Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder
Authors
Kimberly D Kyker
Jean Coffman
Robert E Hurst
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2005
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-5-4

Other articles of this Issue 1/2005

BMC Urology 1/2005 Go to the issue